Company Overview and News


Add VLA
to your dashboard

Headline News

Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug

2018-01-14 seekingalpha
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved. (147-0)

Viralytics attracts funding support from Chinese life sciences company

2018-01-07 proactiveinvestors.com.au
Viralytics Ltd (ASX:VLA) has received a boost for its cancer treatment development work with more than $29.6 million raised in a private placement to a leading Chinese life sciences company. (0-1)

Viralytics targets cash injection for cancer research

2018-01-04 proactiveinvestors.com.au
Viralytics' (ASX:VLA) lead drug CAVATAK® harnesses the common cold virus to infect and kill cancer cells, with a market-leading body of clinical evidence across multiple cancer indications. (0-1)

Viralytics Ltd reveals positive cancer immunotherapy results

2016-11-14 proactiveinvestors.com.au
CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells. The Phase 1b trial is designed to evaluate the safety and tolerability of CAVATAK in combination with KEYTRUDA, in 30 patients with advanced melanoma. According to the preliminary data from the first 10 patients evaluable for best overall tumour response assessment, a disease control rate of 100% was demonstrated.

Appendix 4C - quarterly

2016-04-28 asx.com.au

Viralytics Ltd reports positive results of melanoma cancer fighting combination

2016-04-19 proactiveinvestors.com.au
Viralytics Ltd (ASX:VLA) is focused on developing oncolytic virotherapy for the treatment of a wide range of cancers.

Viralytics Ltd details positive outcome of cancer fighting combination

2016-04-19 proactiveinvestors.com.au
Viralytics Ltd (ASX:VLA) is focused on developing oncolytic virotherapy for the treatment of a wide range of cancers.